BioSpace News Archive

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD).

The American Academy of Orthopaedic Surgeons issued an update to the Clinical Practice Guideline for Surgical Management of Osteoarthritis of the Knee, which replaces the previous edition released in 2015.

Magnolia Medical Technologies, Inc. (“Magnolia Medical”) today announced the publication of unprecedented clinical results from a study performed by Stanford Health Care at Stanford University Medical Center evaluating the impact of Steripath in reducing false-positive diagnostic test results for bloodstream infections (BSIs), including sepsis, and false-positive central line-associated bloodstream infections (CLABSIs).

Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused on the discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce the addition of life sciences veteran Ian Wisenberg to the Company’s board of directors (the “Board”) and as an independent member of the Company’s audit committee.

Psycheceutical Bioscience, Inc. today announced that Dr. Julian Bailes has accepted the role of Chief Medical Officer and will also join the company’s Board of Directors.

On January 9 th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.

Gemina Laboratories Ltd. is pleased to provide the following strategic overview and share an outlook for 2023 and beyond.

Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase an aggregate of 105,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Armata Pharmaceuticals, Inc. today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”), Armata’s largest shareholder.